More Videos
SPECIAL REPORT
MOST SHARED
- GE, Comcast Complete Deal Over NBC Universal: Source
- Keeping America Great
- New Incentive To Improve... Your Home, That Is!
- Hyundai's US Auto Sales Jump 46% in November
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Oil Tomorrow
- Trading 2010 - Gadgets
- Lightning Round OT: Incyte, Randgold Resources and More
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Predictions 2010: Technology
- Predictions 2010: Consumers
- Who Were the Biggest Winners And Losers This Year?
- Look Ahead: Markets Count Down to US Jobs Report
- GE, Comcast Complete Deal Over NBC Universal: Source
- US May Raise Rates Before Jobs Recover: Fed's Plosser
- Cramer: Watch Tech Stocks Wednesday
- New Cash Incentives To Make Home Improvements?
- Stocks Likely Don't Need Santa to Keep Rally Going
- Larry Kudlow's Open Letter to Tiger Woods
- Super Fantasy Christmas Gifts of 2009
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
Source: nejm.org Lilly Effient |
] experimental Alzheimer's drug Dimebon (dim-uh-bahn). In addition to the rest results being compelling, I highlighted the drug because it has an intriguing backstory: Dimebon is an old Russian antihistamine that's being repurposed by MDVN as a potential drug for Alzheimer's and Huntington's Disease. I also did a live interview with MDVN's CEO Dr. David Hung on "Closing Bell" (see video clip) and I asked him whether the promising results would attract a buyer or partner for the company/drug. He replied, "Partnership is certainly one of our options we're considering. There are certainly many reasons why a partnership could be attractive for the company including the fact that most Alzheimer's patients are cared for by a very broad base of providers. But partnership is only one of a number of options we could pursue to develop this drug."
But that's the option he has chosen. This morning the company announced it's doing a Dimebon deal with Pfizer[PFE
Loading...
()
]. On the conference call, Dr. Hung said there was a bidding war, that there were "multiple highly attractive offers from major global pharmaceutical companies." But in the end he went with PFE, in part, due to the point he made during our interview.
Pfizer already sells the Alzheimer's market-leading drug Aricept and Dr. Hung believes the world's biggest drug company has "exceptional commercialization resources and the ability to reach primary care physicians (the broad base of prescribers he cited in our interview)." Not to mention the cash. Pfizer's giving MDVN $225 million up front. And another half-a-billion bucks if/when the Food and Drug Administration approves Dimebon. On top of that, MDVN would get 40 percent of the profits. That's why the stock, which has more than doubled this year, is up big on the news (although it's already well off of its earlier highs).
For Pfizer, of course, that's petty cash. For Medivation, it's transformational. Miller Tabak healthcare analyst, Les Funtleyder, writes in a research note to clients this morning, "(Pfizer) showing signs of life....This deal looks like a positive risk-reward opportunity for PFE. (But) PFE needs to continue to be aggressive if it is to compensate for the major revenue cliff in the next few years." He's referring to Lipitor going generic. And Funtleyder cautions investors from getting too excited. "Alzheimer's is a tricky indication to treat if for no other reason medicine (as in the field of medicine) does not fully understand the disease." Myriad Genetics and Neurochem are among the recent casualties. And the jury's still out on Wyeth[WYE
Loading...
()
] and Elan's [ELN
Loading...
()
]drug.
P.S. Blog reader Mario Cavallini was kind enough to email me to let me know that he, too, had spotted the Eli Lilly "Coming Soon" ad for Effient on the "New England Journal of Medicine" website that I blogged about yesterday. But he went even further, refreshing the homepage on his own and sending me a screengrab of the ad which had been moved from a banner above the masthead to the left margin.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes